Amneal Pharmaceuticals (AMRX) Misses Q1 EPS by 1c; Offers FY22 Guidance

Amneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.12, $0.01 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $498 million versus the consensus estimate of $503.97 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2022 EPS of $0.80-$0.85, versus the consensus of $0.84. Amneal Pharmaceuticals sees FY2022 revenue of $2.15-2.25 billion, versus the consensus of $2.19 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM